Pepcid
Executive Summary
H2 antagonist sales grew 13% during the quarter. In recognition of the upcoming loss of exclusivity for Pepcid, Merck tried to minimize the significance of the increase. Underlying prescriptions were down 15%-20%, Jordan said, and only an unusual inventory adjustment in the second quarter of 1999 led to the reported sales increase. "It is very important to remember that Pepcid is one of Merck's most aggressively priced products in terms of rebates and discounts [and that] Pepcid carries a royalty to a third party," she added. Merck reports gross sales without adjustments for rebates and other payments
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: